Stay updated on ARO-APOC3 in Mixed Dyslipidemia Clinical Trial
Sign up to get notified when there's something new on the ARO-APOC3 in Mixed Dyslipidemia Clinical Trial page.

Latest updates to the ARO-APOC3 in Mixed Dyslipidemia Clinical Trial page
- CheckyesterdayChange DetectedRevision tag on the page updated from v3.5.3 to v3.5.4, indicating a metadata/version update. This change represents an internal versioning update and does not alter the study details or displayed information.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, indicating a site update rather than a change to the ClinicalTrials.gov study details.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision notes show the current release as Revision: v3.5.2 with dates 2026-04-14, 2026-04-10, and 2026-04. A prior Revision: v3.5.0 dated 2026-02-24, 2026-02-06, and 2026-02 has been removed.SummaryDifference0.2%

- Check58 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page.SummaryDifference0.0%

- Check72 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check79 days agoChange DetectedResults were posted on 2026-02-24 and the study record was updated to reflect the new title 'Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia (MUIR)' with expanded design details and endpoints.SummaryDifference5%

Stay in the know with updates to ARO-APOC3 in Mixed Dyslipidemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARO-APOC3 in Mixed Dyslipidemia Clinical Trial page.